Project Details
Description
Proposal Title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer
| Status | Active |
|---|---|
| Effective start/end date | 2/1/17 → 12/31/25 |
Funding
- SEAGEN INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.